Regarding vandetanib, among patients treated under phase 3 ZETA study, RET mutation in tumor cells was present in 52% of patients, no RET mutation was not detected in 2.7%, whereas in 45.3%, RET mutation status was unknown. The gene discussed is RET; the disease is neoplasm.